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ABSTRACT 18 
 19 
Brain renin-angiotensin system (RAS) hyperactivity has been implicated in the development and 20 
maintenance of hypertension. Angiotensin III, generated by aminopeptidase A (APA), one of the 21 
main effector peptides of the brain RAS, exerts a tonic stimulatory control over blood pressure in 22 
hypertensive rats. This identified brain APA as a potential therapeutic target for the treatment of 23 
hypertension, leading to the development of RB150 an orally-active prodrug of the specific and 24 
selective APA inhibitor, EC33. When given orally, RB150 crosses the gastrointestinal and blood-25 
brain barriers, enters the brain, generates two active molecules of EC33 which inhibit brain APA 26 
activity, blocking brain angiotensin III formation, and decrease blood pressure for several hours 27 
in hypertensive rats. The RB150-induced blood pressure decrease is due to a reduced vasopressin 28 
release, which increases diuresis, reducing extracellular volume, a decrease in sympathetic tone, 29 
leading to a reduction of vascular resistances and the improvement of the baroreflex function. 30 
RB150 was renamed firibastat by the WHO. Phase Ia/Ib clinical trials showed that firibastat is 31 
clinically and biologically well-tolerated in healthy volunteers. Clinical efficacy of firibastat in 32 
hypertensive patients was therefore demonstrated thanks to two Phase II studies. Overall, 33 
firibastat could represent the first drug of a new class of antihypertensive agents targeting the 34 
brain RAS. 35 
  36 
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Hypertension affects one third of the adult population and is the leading cause of premature 37 
death and disability‐adjusted life years 1,2. It is a major risk factor for many diseases including 38 
coronary heart disease, cerebral vascular accidents, cardiac failure and renal dysfunction. Despite 39 
existing therapy, hypertension remains poorly controlled worldwide 3, and its prevalence is 40 
increasing due to ageing of the population and the obesity epidemic 4. The prevalence of 41 
hypertension among U.S. adults aged >18 years was 29% and even higher among Non-Hispanic 42 
black adults (40.6%) 5. In African-Americans, hypertension is more severe with a higher morbidity 43 
and mortality than in Whites 6. Among the many effective antihypertensive drugs currently used, 44 
are inhibitors of the systemic renin-angiotensin system (RAS). These include drugs that inhibit 45 
formation of angiotensin II (AngII) by angiotensin I -converting enzyme (ACE, EC 3.4.15.1), called 46 
ACE inhibitors (ACEI)  and agents that block the action of AngII on type 1 AngII receptors (AT1) by 47 
AT1 receptor antagonists (ARB) 7. However, secondary effects of ACE inhibitors, such as cough and 48 
more rarely angioedema have been observed 8. Renal function may also deteriorate in underlying 49 
renal artery stenosis 9. In addition, blockers of the systemic RAS are poorly effective in African-50 
Americans in whom high BP is often accompanied by a low-renin state (decrease in systemic RAS 51 
activity) and high plasma arginine-vasopressin levels 6,10. Monotherapy for hypertension 52 
treatment is ineffective in more than half of all cases and responses to a given compound, 53 
regardless of its chemical family, differ greatly between individuals. Most hypertensive patients 54 
require two or more antihypertensive drugs to control BP including a RAS blocker, a calcium 55 
channel blocker or a diuretic 11–13. Adding to the challenges in controlling blood pressure (BP) in 56 
patients with hypertension, is the growing incidence of resistant hypertension (15%) where at 57 
least three antihypertensive drugs (including a diuretic) are required 14,15. Accordingly, there is a 58 
real clinical need to develop novel classes of antihypertensive agents acting on new targets, with 59 
diversified modes of action, to better manage BP control.  60 
 61 
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The brain renin-angiotensin system 62 
In addition to the systemic RAS, the brain RAS plays an important role in the control of 63 
cardiovascular function and BP regulation 16–18. All components of the systemic RAS, ie, the 64 
precursor angiotensinogen, the enzymes, renin (EC 3.4.23.15), angiotensin I-converting enzyme 65 
(ACE, EC 3.4.15.1), angiotensin converting enzyme type 2 (ACE2, EC 3.4.17.23), aminopeptidase A 66 
(APA, EC 3.4.11.7) and aminopeptidase N (APN, EC 3.4.11.2), the peptides AngI, AngII, AngIII, 67 
AngIV, Ang1-7 and the AngII receptors, type 1 (AT1), and type 2 AngII (AT2) receptors as well as 68 
the Mas receptor (MasR) are present within the brain (reviewed in 19–21) (Figure 1). 69 
Hyperactivity of the brain RAS has been implicated in the development and maintenance of 70 
hypertension and its interruption by either pharmacological or genetic means is associated with 71 
a profound beneficial outcome in hypertension 16,17; its components could constitute interesting 72 
targets for treatment of hypertension.  73 
Aminopeptidase A and Aminopeptidase N Inhibitors  74 
AngII is hydrolysed to numerous peptides, which themselves may have functional significance. 75 
The best candidate enzymes involved in the hydrolysis of AngII and AngIII include two membrane-76 
bound zinc-metallo-peptidases : APA and APN 22–24. This is based on the observation that in vitro 77 
purified APA hydrolyses the N-terminal aspartate residue from AngII to generate AngIII25 and that 78 
purified APN cleaves the N-terminal arginine of AngIII to generate AngIV 26.  79 
To demonstrate that APA and APN are involved in vivo in the metabolism of brain 80 
angiotensins, specific and selective APA and APN inhibitors were required. APA inhibitors have 81 
been developed by rational design taking into account APA substrate specificity, APA 82 
exopeptidase activity and the presence of the Ca2+ and Zn2+ atoms in the APA active site 27. Some 83 
of these potential inhibitors were based on the structure of the glutamate thiol (GluSH), which is 84 
a potent but non-selective inhibitor of APA and APN 28 . In this context, Chauvel et al. 29 designed 85 
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an APA inhibitor, EC33 ((S)-3-amino-4-mercapto-butyl sulfonic acid), in which the GluSH 86 
carboxylate side-chain was replaced by a sulfonate (Figure 4). This resulted in an increase of the 87 
polarity of the sulfonate side chain and in its interaction with the calcium ion, thus improving 88 
selectivity towards APA 29. In addition, an effective APN inhibitor was developed: PC18 (2-amino-89 
4-methylsulfonyl butane thiol) 30. Pharmacological characterization of these inhibitors performed 90 
on purified APA and APN showed that EC33 inhibited APA (Ki = 0.29 μM) almost 100 times more 91 
strongly than APN. Conversely, PC18 inhibited APN (Ki = 0.008 μM) 2150 times more efficiently 92 
than APA (Ki = 17.2 μM) 30,31. A systemically active prodrug of EC33, RB150 (4,4´-dithio bis[3-amino 93 
butyl sulfonic acid]) (Figure 4) was also developed. This inhibitor comprises two molecules of EC33 94 
linked by a disulfide bridge. As the thiol group of RB150 is engaged in the disulfide bridge, it cannot 95 
inhibit APA enzymatic activity since it is unable to interact with the zinc atom present in the APA 96 
active site and essential for its catalytic activity. However, the disulfide bridge allows orally 97 
administered RB150/firibastat to cross the intestinal, hepatic and blood–brain barriers. On entry 98 
into the brain, it is cleaved by brain reductases to generate two active molecules of EC33. 99 
Moreover in vitro, the reduced form of RB150 obtained in the presence of dithiothreitol (DTT) 100 
inhibited purified APA (Ki = 0.20 ± 0.02 μM), similar to EC33 32. The selectivity of EC33 and RB150 101 
toward APA was shown by the lack of affinity of these compounds for other zinc metalloproteases 102 
involved in the production or metabolism of vasoactive peptides, such as APN, ACE, ACE-2, ECE-1 103 
and NEP, as well as by the absence of binding of these compounds to AT1 and AT2 or endothelin 104 
A and B receptors known to be involved in BP regulation 33. 105 
More recently, a new more potent and selective central-acting APA inhibitor prodrug, 106 
NI956/QGC006, was developed 34. This compound was obtained by disulfide bridge-mediated 107 
dimerization of NI929 ((3S,4S)-3-amino-4-mercapto-6-phenyl-hexane-1-sulfonic acid), a non-108 
peptidic APA inhibitor that is 10 times more potent than EC33 at inhibiting recombinant mouse 109 
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APA activity in vitro (Ki value of 30 nM). NI956 did not inhibit other enzymes (ACE, ACE2) or 110 
receptors (AT1, AT2, endothelin type A and B, vasopressin type1 and type 2, apelin, bradykinin 111 
and urotensin II) involved in BP control when tested at 10-5 M. 112 
Distribution of APA in the Brain in Parallel with AT1 Receptors  113 
APA enzymatic activity measured  in the absence or presence of the specific and selective APA 114 
inhibitor, EC33, has also been identified in rat brain nuclei involved in the control of body fluid 115 
homeostasis and cardiovascular functions 35. The lowest and highest levels differed by a factor of 116 
150. The pituitary gland and circumventricular organs were the richest source of this enzyme, 117 
followed by the median eminence, the arcuate nucleus, the choroid plexus, the hypothalamic 118 
paraventricular (PVN) and supraoptic (SON) nuclei, the area postrema (AP), the lateral reticular 119 
nucleus (LRN) and the nucleus of the solitary tract (NTS) (Figure 2C) 35. There is a good relationship 120 
between the brain distribution of APA activity, angiotensin receptors 19,36 (Figures 2A-2B) and 121 
nerve terminals 37. 122 
In the human brain, immunostaining of sections through the medulla oblongata shows a high 123 
density of APA immunoreactive neuronal cell bodies and fibers in the motor hypoglossal nucleus 124 
(XII), the dorsal motor nucleus of the vagus (X), the nucleus of the solitary tract (NTS), the Roller 125 
nucleus and the nucleus ambiguus 38 (Figure 2D). APA immunoreactivity was also visualized in 126 
vessels and capillaries in the dorsal motor nucleus of the vagus and the inferior olivary complex 127 
38. Thus, there is clear evidence demonstrating that brain APA may be associated not only with 128 
neuronal cells, but also with microvessels. 129 
The presence of APA in several brain nuclei containing angiotensin nerve terminals and AT1 130 
receptors involved in BP regulation suggests that APA is an integral component of the brain RAS 131 
in humans and rodents and further supports the idea that APA inhibitors could be clinically tested 132 
as an additional therapy for the treatment of certain forms of hypertension. 133 
 134 
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In Vivo Metabolic Pathways of Brain AngII and AngIII 135 
Harding et al. were the first to investigate the metabolism of brain AngII and AngIII in vivo 39. 136 
They reported that the half-lives of intracerebroventricularly (i.c.v) injected AngII and AngIII were 137 
approximately 23 and 8 seconds, respectively, indicating that AngIII is metabolized more rapidly 138 
than AngII. To block AngII and AngIII metabolism, they used the aminopeptidase inhibitors, 139 
amastatin and bestatin, and showed that the administration of both inhibitors i.c.v extended the 140 
half-lives of 125IAngII and 125IAngIII 40,41. These results indicate that amastatin and bestatin are 141 
efficient blockers of angiotensin metabolism. However they are not selective with respect to AngII 142 
and AngIII. Consistent with this, amastatin, which was initially described as a specific APA 143 
inhibitor, actually inhibits APN 40 times more efficiently than APA, whereas bestatin displays 144 
broad specificity for various aminopeptidases 42,43. In vivo studies showed that the APA inhibitor, 145 
EC33 (1–100µg) injected by i.c.v route in conscious mice inhibited brain APA activity in a dose-146 
dependent manner with an IC50 of 12 µg 32. EC33, i.c.v co-injected with radiolabeled AngII into 147 
conscious mice, completely blocked the formation of [3H]AngIII in the hypothalamus 44, whereas 148 
the APN inhibitor, PC18, increased the half-life of [3H]AngIII by a factor of four 31. These results 149 
provided the demonstration that APA is involved in vivo in the formation of brain AngIII from AngII 150 
whereas APN metabolizes AngIII in AngIV. 151 
Brain AngIII in the Control of Blood Pressure 152 
The notion that the physiologically relevant peptide in the brain RAS responsible for the 153 
regulation of BP is AngIII rather than AngII was suggested in 2003 45,46. Since then many studies 154 
have supported the “AngIII hypothesis”. AngII and AngIII display similar affinity for AT1 and AT2 155 
receptors 47. In addition, these peptides have a similar affinity for a non-AT1, non-AT2 angiotensin 156 
binding site which shares some characteristics with the liver cytosolic AngII binding proteins, later 157 
identified as EC 3.4.24.15 (thimet oligopeptidase) and/or EC 3.4.24.16 48. Harding et al. 158 
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demonstrated, in a push–pull cannula study, that 93% of the angiotensin material released in the 159 
PVN, after simulation with veratridine or by water deprivation, was in the form of AngIII whereas 160 
only 6.8% corresponded to authentic AngII 49. AngII and AngIII, when centrally administrated, 161 
similarly increase BP, stimulate vasopressin release and decrease baroreceptor reflex function 162 
20,44,50–52.  163 
AngII and AngIII increase BP by three mechanisms: (i) increase in sympathetic nerve activity, (ii) 164 
synaptic inhibition of the baroreflex in the nucleus of the tractus solitarius, and (iii) release of AVP 165 
into the bloodstream 53.To determine the respective roles of AngII and AngIII in the central control 166 
of BP, the effects of AngII and AngIII, injected by i.c.v route, on BP in hypertensive rats were 167 
studied in the absence and presence of APA or APN inhibitors, EC33 and PC18 respectively. Two 168 
experimental models of hypertension were used: the SHR, a genetic model of hypertension 169 
sensitive to systemic RAS blockers, and the DOCA-salt rat, a salt- and volume-dependent but 170 
renin-independent (low plasma renin levels) model of hypertension resistant to systemic RAS 171 
blockers. Both models exhibited an hyperactivity of the brain RAS. 172 
Central treatment with the APA inhibitor EC33 blocked the pressor effect of i.c.v AngII in 173 
anaesthetized SHRs, suggesting that the increase in BP requires the conversion of AngII into AngIII 174 
54. The i.c.v injection of EC33 alone leads to an immediate and total inhibition of brain APA activity, 175 
thus blocking, in the brain, the formation of AngIII and inducing an decrease in BP in hypertensive 176 
DOCA-salt rats and SHRs 32,54 (Figure 3). In contrast, a high intravenous (i.v) dose of EC33 did not 177 
modify BP in hypertensive rats, demonstrating that the i.c.v EC33-induced decrease in BP is a 178 
central but not due to a systemic effect 32 (Figure 3). 179 
Together these findings indicate that AngIII is the effector peptide of the brain RAS. This 180 
conclusion was further supported by the significant increase in BP induced by the APN inhibitor 181 
PC18, when injected alone, by the i.c.v route, into SHR rats 54. This pressor response is blocked by 182 
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prior injection of the AT1 antagonist losartan (but not by the AT2 antagonist PD 123319), 183 
indicating the specificity of action of APN on AngIII metabolism and the involvement of AngIII in 184 
the PC18-induced increase in BP. By blocking the action of APN, PC18 causes an accumulation of 185 
endogenous brain AngIII, which in turn results in an increase in BP, through interaction with AT1 186 
receptors. Finally, the complete inhibition, by EC33, of the PC18-induced increase in BP 187 
demonstrates the existence of the endogenous enzymatic cascade: AngII generated AngIII, itself 188 
metabolized in AngIV, mediated by the activities of APA and APN 54. 189 
Consistent with these data, Wright et al. studied the BP effects of AngII and AngIII analogs, 190 
D-Asp1AngII and D-Arg1AngIII, which were slightly less degraded than the endogenous 191 
corresponding peptides. They injected these compounds, i.c.v into conscious normotensive rats 192 
in the presence and absence of EC33 and PC18 46 and concluded that AngIII was a centrally active 193 
ligand of the brain RAS, important in the control of BP. The interpretation of these results was 194 
however challenged by Kokje et al. 55, who injected (i.c.v) AngII analogs that were more resistant 195 
to aminopeptidase degradation such as N-methyl-L-Asp1-AngII into conscious normotensive rats. 196 
They found that this compound is very slowly degraded and increases BP through AT1 receptor 197 
activation. They concluded  that AngII, rather than AngIII, is the main active form controlling BP 198 
in the brain. However, the finding that i.c.v injection of this analog, which binds AT1 receptors 199 
very efficaintly, was expected to increase BP. In fact, in contrast to AngII, which, even in the 200 
presence of an APA inhibitor, may be rapidly degraded by other peptidases, such dipeptidyl 201 
aminopeptidases, endopeptidases or ACE2, giving rise to Ang3-8 (AngIV), Ang1-5, Ang4-8, and 202 
Ang1-7, all being inactive on AT1 receptors, N-methyl-L-Asp1-AngII is only metabolized in Ang2-203 
5. N-methyl-L-Asp1-AngII then remains in major part under its native form, activating AT1 204 
receptors. This underlines the different metabolism profiles of endogenous AngII and exogenous 205 
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N-Methyl-L-Asp1-AngII. This illustrates the difficulty to use exogenous metabolically resistant 206 
AngII analogs to understand the mechanisms of action of endogenous AngII and AngIII peptides. 207 
Moreover, Wright et al., showed that, despite the high molecular mass of APA and APN 208 
(approximately 120–130 kDa for the monomer), i.c.v infusion of APA produces a significant 209 
increase in BP 56, whereas i.c.v infusion of APN in SHR rats decreases BP 57. The pressor effect 210 
probably results from a higher level of production of brain AngIII, whereas the hypotensive effect 211 
might be related to an increase in AngIII metabolism. Finally, i.c.v infusion of an antiserum that 212 
inhibited APA activity reduced the AngII-induced BP increase by 59 % 58.  213 
Together, these studies suggest that brain APA, the enzyme responsible for generating 214 
brain AngIII, might be a promising target for hypertension treatment, justifying the development 215 
of potent and selective APA inhibitors as centrally-acting antihypertensive agents.  216 
New targets to treat hypertension - Brain Penetrating APA Inhibitor Prodrugs as Centrally 217 
Acting Antihypertensive Drugs 218 
While EC33 is an effective centrally acting APA inhibitor, it does not cross the blood brain barrier 219 
and hence has limitations for clinical use.  However RB150, a prodrug of EC33, was developed and 220 
found to be an effective orally active agent 32,33,59. When given by oral route, RB150 crosses the 221 
intestinal, hepatic, and blood-brain barriers and enters the brain. Once in the brain, the disulfide 222 
bridge of RB150 is immediately cleaved by brain reductases generating two active molecules of 223 
EC33, which inhibit brain APA activity, block formation of brain AngIII and decrease BP and AVP 224 
release in conscious hypertensive rats. In alert DOCA-salt rats, the RB150-induced BP decrease is 225 
evident 2 h after administration, maximal between 5 and 9 h, and persists after 15 h but without 226 
significance; after 24  hours, the drug effect is no longer evident (Figure 4) 60. 227 
The impressive antihypertensive effect of RB150 is attributed to three different mechanisms: (i) 228 
decrease in vasopressin release from the posterior pituitary into the blood circulation increased 229 
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diuresis and reduced extracellular volume, (ii) decrease in sympathetic tone, decreased vascular 230 
resistance and (iii) improved baroreflex function (Figure 5) 33,59,61. RB150 has no effect on BP in 231 
normotensive rats that display hyperactivation of brain aminopeptidase A and brain RAS. Thus, 232 
RB150 acts as an antihypertensive agent and not as a hypotensive agent 33,59. In addition, we 233 
showed in conscious SHRs that concomitant oral administration of RB150 with enalapril, an ACE 234 
inhibitor, potentiated the RB150-mediated decrease in BP compared with the BP decrease 235 
induced by RB150 or enalapril alone 59. This was especially evident in the acute phase with lower 236 
doses. One hour after administration, RB150 at at 100 mg/kg or enalapril at 1mg/kg did not induce 237 
any significant BP change, whereas in combination there was a significant BP decrease (-16.4 ± 238 
3.1 mm Hg) 59. Accordingly we propose that the synergistic effects of combined RB150 with an 239 
ACE inhibitor or an AT1 receptor antagonist, may have improved therapeutic effects in the 240 
management of patients with hypertension. This may relate to combined inhibition of both the 241 
brain and the systemic RAS. 242 
Moreover, oral NI956/QGC006 treatment in hypertensive DOCA-salt rats exhibited a high potency 243 
for normalizing brain APA hyperactivity and BP for 10 hours after a single administration, 244 
decreasing plasma AVP levels, and increasing diuresis and natriuresis, without affecting plasma 245 
sodium and potassium concentrations, at a dose one tenth that required for RB150 34. Therefore, 246 
NI956/QGC006 is a “best-in-class” central-acting APA inhibitor prodrug, belonging to the same 247 
drug class as RB150, supporting the development of antihypertensive therapies targeting brain 248 
APA. 249 
These observations not only establish a method for the central delivery of an APA inhibitor but 250 
provide insights into the role of brain AngIII in the regulation of vasopressin release and BP in 251 
alert DOCA-salt and spontaneously hypertensive rats (SHR). This constituted the first step in the 252 
development of a potentially new class of orally active antihypertensive drugs and in 2012, RB150 253 
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was selected for clinical development. Toxicology, safety pharmacology and pharmacokinetics 254 
studies demonstrated that RB150 is well-tolerated both in rats and dogs up to a dose of 1000 255 
mg/kg during 28 days 59. 256 
Phase I Clinical Trials of Firibastat in Human Volunteers 257 
In a first-in-human study (Phase Ia clinical trial) 62, the safety/tolerability, pharmacokinetics and 258 
pharmacodynamic effects of single ascending doses of RB150, renamed firibastat by the World 259 
Health Organization, were determined in humans. Healthy male volunteers (n=56) were randomly 260 
assigned to receive single oral doses from 10 to 1250 mg of firibastat or placebo. No severe or 261 
life-threatening adverse effects were observed. The only treatment-emergent adverse effect 262 
considered to be probably related to study treatment was one event of orthostatic hypotension, 263 
which occurred in one subject in the 500 mg group. No clinically significant abnormalities were 264 
observed in laboratory safety parameters, the haematology panel or clinical chemistry values, 265 
vital signs including haemodynamic parameters, or in ECG readings 62. Pharmacokinetic analysis 266 
demonstrated good dose proportional exposure to firibastat and confirmed that once or twice a 267 
day oral dosing could be a suitable regimen for further studies. Compared with placebo, firibastat 268 
did not significantly change the concentrations of plasma renin, plasma and free urine 269 
aldosterone, plasma and urine cortisol, and plasma copeptin, a biomarker of AVP release. No 270 
significant change was observed for supine HR, systolic BP and diastolic BP in any of the treatment 271 
groups 62. In a second clinical study (Phase Ib), we confirmed the safety and the tolerability of a 272 
single dose up to 2000 mg and multiple oral doses of firibastat up to 750 mg b.i.d. during 7 days 273 
in healthy adult subjects (F. Balavoine, M. Azizi, D. Bergerot, N. De Mota, R. Patouret, B. P. Roques 274 
and C. Llorens-Cortes unpublished work) (NCT01900171 & NCT01900184). In conclusion, 275 
firibastat was shown to be safe and well tolerated following oral administration of ascending 276 
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single oral doses up to 2000 mg and repeated oral doses up to 750 mg twice daily for 7 days in 277 
healthy subjects. 278 
Phase IIa Clinical Trial of Firibastat in Hypertensive Patients 279 
Following the successful phase I studies, effects of firibastat on BP were assessed in patients. 280 
Studies to assess the safety, tolerability, and BP effects by inhibiting brain APA with firibastat were 281 
studied for four weeks, in patients with primary hypertension in a phase IIa multicenter double-282 
blind randomized placebo-controlled crossover study (NCT02322450) 63. Firibastat, at a dose of 283 
250 mg twice daily for one week, with forced titration to 500mg twice daily for three weeks, 284 
decreased in the intention-to-treat population (34 patients), daytime ambulatory systolic BP and 285 
office systolic BP decreased by 2.7 and 4.7 mmHg respectively vs. placebo, but the difference 286 
between the groups was not statistically significant (Table 1). In the per-protocol population (29 287 
patients), in patients with a basal value of daytime ambulatory systolic BP between 154 and 172 288 
mmHg, firibastat treatment induced a larger decrease in daytime ambulatory systolic BP (median 289 
[interquartile range (IQR)]: -9.4 [-12.5 to -3.0] mmHg), whereas placebo treatment did not induce 290 
any change (median [IQR]: 0.75 [-5.5 to -1.9] mmHg). In the multiple linear regression analysis for 291 
the per-protocol population, only treatment with firibastat (P=0.06) and baseline daytime 292 
ambulatory SBP (P=0.01) were associated with changes in daytime ambulatory systolic BP but not 293 
with plasma renin activity 63. This suggests that the more the basal daytime ambulatory systolic 294 
BP is elevated, the more the firibastat-induced systolic BP decrease is majored 63. This is in 295 
agreement with the observation that, in experimental models of hypertension, firibastat acted as 296 
an antihypertensive agent and not as a hypotensive agent. This study showed that brain APA 297 
inhibition with firibastat, in patients with mild hypertension, was safe and tended to decrease 298 
daytime ambulatory systolic BP relative to placebo at 4 weeks. However, because this was a pilot 299 
study, aiming mostly at the safety and tolerability of firibastat, the number of patients involved 300 
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was small, and the duration of the treatment too short and the baseline daytime systolic BP not 301 
enough high to definitively conclude on the antihypertensive effect of firibastat in humans. 302 
Phase IIb Clinical Trial of Firibastat in Overweight Hypertensive Patients 303 
The results of the Phase IIa study were used to guide the design of a clinical trial Phase IIb, NEW 304 
HOPE (NCT03198793) 64. NEW-HOPE was a multicenter, open-label phase II study in 40 US centers 305 
performed in 256 patients overweight or obese (BMI 25-45kg/m2) hypertensive (systolic BP 145-306 
170 mmHg) patients, including 54% African and Hispanic individuals. After a two-week wash-out 307 
period, patients received firibastat for 8 weeks (250 mg twice daily orally for two weeks, then 500 308 
mg twice daily if automated office BP [AOBP] >140/90 mmHg; hydrochlorothiazide 25 mg q.d was 309 
added after 1 month if AOPB ≥160/110 mmHg).  310 
The primary endpoint corresponding to change from baseline in systolic automatic office BP 311 
(AOBP, SPRINT method) met a significant decrease of 9.5 mmHg 64 (p <0.0001) (Table 1). Systolic 312 
AOBP similarly decreased in African-Americans by 10.5 mmHg (p <0.0001) and in Non-Blacks by 313 
8.9 mmHg (p <0.0001) (Table 1). 85% of the subjects did not receive hydrochlorothiazide and were 314 
treated with firibastat alone 64. Most frequent adverse events were headaches (4%) and skin 315 
reactions (3%). No angioedema was reported. No change in potassium, sodium and creatinine 316 
blood level were observed. 317 
Firibastat may be an attractive potential alternative therapy for African-Americans. In African-318 
Americans, hypertension occurs earlier, is more severe, controlled less often and has a higher 319 
morbidity and mortality than in Whites. African-Americans are also less responsive to 320 
monotherapy with ACEIs or ARBs 6. Obesity, higher salt-sensitivity and low plasma renin activity 321 
are possible reasons of this poor BP control 65. The efficiency of firibastat to decrease systolic BP 322 
in African-Americans is in agreement with the preclinical studies showing that RB150/firibastat is 323 
highly efficient in an experimental salt-dependent model of hypertension with low plasma renin 324 
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levels and high plasma vasopressin levels, resistant to systemic RAS blockers 27. The clinical data 325 
on firibastat were recently reviewed by Azizi et al.66. 326 
Conclusions 327 
Growing evidence confirms involvement of the brain RAS in the development of hypertension. 328 
Targeting this system with novel agents, such as the first-in-class APA inhibitor prodrug 329 
RB150/firibastat has been shown to be very effective. RB150/firibastat crosses the blood-brain 330 
barrier after oral administration and thereby inhibits brain APA activity, blocking formation of 331 
brain AngIII, one of the main effector peptides of the brain RAS exerting a tonic stimulatory action 332 
on BP control in hypertensive rats. This led in turn to a normalization of BP, especially effective in 333 
salt-sensitive hypertension. Clinical trials Phase IIa and IIb provide pharmacological proof-of-334 
principle for the efficacy of brain APA inhibition for decreasing BP in hypertensive patients, 335 
especially in African-Americans patients, where monotherapy with ACE inhibitors or AT1 receptor 336 
antagonists may be less effective. In an era when there are few innovations in antihypertensive 337 
drug development, if the proof of concept of firibastat efficacy is confirmed in pivotal Phase III 338 
trials, firibastat treatment could provide new hope for improved and better management of 339 
hypertension, and may be especially beneficial in subgroups of hypertensive patients, such as 340 
those with low renin hypertension, difficult to treat hypertension or resistant hypertension.  341 
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Figure Legends 566 
 567 
Figure 1. Schematic diagram of the brain renin-angiotensin system.  568 
ACE: angiotensin I -converting enzyme; APA: Aminopeptidase A; APN: Aminopeptidase N; ACE2: 569 
angiotensin-converting enzyme type 2; AT1: angiotensin type 1 receptor; IRAP: Insulin-Regulated-570 
Aminopeptidase. 571 
 572 
Figure 2. Distribution of mRNA for the AT1A, AT1B and AT2 receptors and APA in the brain 573 
(A) Distribution of mRNA for the AT1A, AT1B and AT2 receptors in the adult rat brain, sagittal 574 
section. (adapted from 19) - (B) Dark-field photomicrograph of sections showing the distribution 575 
of AT1A receptor mRNA in the adult rat brain. The labelling is very high in the subfornical organ 576 
(SFO), the vascular organ of the lamina terminalis (OVLT), the median preoptic nucleus (MnPO), 577 
the hypothalamic paraventricular nucleus (parvocellular part), the nucleus of the solitary tract 578 
(NTS) and the area postrema (AP).  Scale bar=1 mm (adapted from 36) - (C) Distribution of APA 579 
enzymatic activity in the adult rat brain. (adapted from 35). – (D) APA immunoreactivity in the 580 
human intermediate medulla oblongata (adapted from 38) Photomicrographs of human APA 581 
immunoreactive somata or fibers in the motor hypoglossal nucleus (XII), the dorsal motor nucleus 582 
of the vagus (X), the nucleus of the solitary tract (Sol) and APA immunoreactive vessels (asterisks) 583 
in the dorsal motor nucleus of the vagus. (Abbreviations: APit, anterior pituitary; ARC, arcuate 584 
nucleus; AT1, angiotensin receptor type 1; AT2, angiotensin receptor type 2; IO, inferior olive; LS, 585 
lateral septum; LC, locus coeruleus; LRN, lateral reticular nucleus; MeA, medial amygdaloid 586 
nucleus; ME, median eminence; MED, medial cerebellar nucleus; MG, medial geniculate complex; 587 
MPO, medial preoptic nucleus; Pir, piriform cortex; PPit, posterior pituitary; PV, periventricular 588 
nucleus; R, red nucleus; RF, Reticular Formation; RVLM, rostral ventrolateral medulla; SON, 589 
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supraoptic nucleus; Sth, subthalamic nucleus; Th, thalamus; XII, hypoglossal nucleus, X, dorsal 590 
motor nucleus of the vagus. 591 
 592 
Figure 3. Effects of the APA inhibitor, EC33 on brain APA activity, hypothalamic [3H]AngIII 593 
formation and blood pressure. 594 
(A) Time course of the inhibition of brain APA activity after the i.c.v injection of EC33 (100 µg) in 595 
alert mice (adapted from 32)  - (B) Percentage [3H]AngIII formation in the hypothalamus 1.5 min 596 
after the i.c.v injection of [3H]AngII in alert mice in the presence or absence of EC33 (30 µg) 597 
(adapted from 32) . Values after APA inhibitor treatment were compared with the control values 598 
obtained after saline injection - (C) Central and systemic effects of the APA inhibitor EC33 on BP 599 
in conscious DOCA-salt rats and SHR (adapted from 32,54). Mean ± SEM changes in mean BP 600 
(ΔMABP in mmHg) following i.c.v injection of EC33 (10–100μg) into alert DOCA-salt rats and SHR 601 
and i.v injection of EC33 (45mg/kg) into alert SHR. Mean BP values obtained after the injection of 602 
EC33 were compared with the baseline mean BP obtained after the injection of saline. *P<0.05 603 
and **P<0.01, *** P<0.001 vs. control values. 604 
 605 
Figure 4. Effects of RB150 given by oral route on brain APA activity and blood pressure in alert 606 
DOCA-salt rats. 607 
(A) Dose-response inhibition of brain APA activity 3.5 hours after the oral administration of RB150 608 
(7.5 to 50 mg/kg) in conscious DOCA-salt rats or WKY. Mean ± SEM of 3 to 16 animals for each set 609 
of conditions. * P<0.05 vs. control values. # P<0.05 vs. DOCA-salt rats non-treated - (B) Mean 610 
arterial BP changes in conscious DOCA-salt rats after oral RB150 administration. Peak changes in 611 
arterial BP (∆MABP in mmHg, mean ± SEM) after oral RB150 administration (0.1 to 30 mg/kg) in 612 
conscious DOCA-salt rats. (n= 7 for each dose) (adapted from 33). 613 
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 614 
Figure 5. Mode of action of the APA inhibitor prodrug, RB150/firibastat, on the control of BP in 615 
hypertensive rats. 616 
The brain RAS controls BP via three different mechanisms according to 53. 1) an increase in 617 
vasopressin release from the posterior pituitary into the bloodstream, 2) an activation of 618 
sympathetic premotor neuron activity at the level of the rostral ventrolateral medulla (RVLM), 619 
and 3) an inhibition of the baroreflex at the level of the nucleus of the solitary tract (NTS). The 620 
conversion of AngII into AngIII in the brain involves APA. RB150/firibastat, the prodrug of the APA 621 
inhibitor EC33, is composed of 2 molecules of EC33 linked by a disulfide bridge. After oral 622 
administration, the disulfide bridge enables RB150/firibastat to cross the blood-brain barrier and 623 
to penetrate the brain. In the brain, the disulfide bridge of RB150/firibastat is cleaved by 624 
reductases releasing 2 active molecules of EC33, inhibiting APA activity. Consequently, brain AngII 625 
is not cleaved into AngIII, which exerts in brain structures a stimulatory action on the control of 626 
BP in hypertensive rats. This results in a BP decrease via a decrease in vasopressin release and 627 
sympathetic neuron activity. (Abbreviations: APit, anterior pituitary; NTS, nucleus of the solitary 628 
tract; PPit, posterior pituitary; PVN, paraventricular nucleus; RVLM, rostral ventrolateral medulla; 629 
SFO, subfornical organ; SON, supraoptic nucleus. (adapted from 59). 630 
